Inzlingen, Germany

Philipp Mueller

USPTO Granted Patents = 1 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Inventor Philipp Mueller

Introduction

Philipp Mueller is a notable inventor based in Inzlingen, Germany. He has made significant contributions to the field of immunology through his innovative research and patent.

Latest Patents

Philipp Mueller holds a patent titled "Screening for compounds having immunosuppressant activity by testing impact on leukocyte-specific calcium fluxes." This invention relates to an assay designed for the identification of compounds with immunosuppressant activity. The assay analyzes whether a candidate compound blocks the Caflux in coronin 1 expressing cells and/or in coronin 1 negative cells. A candidate compound is identified as having immunosuppressant activity if it specifically blocks the Caflux in coronin 1 expressing cells. The patent further describes upstream assays that measure the impact of a candidate compound on coronin 1 trimerization, as well as downstream assays that determine the effects on diacyl glycerol (DAG) generation, phosphatidylinositol-4,5-biphosphate (PIP) levels, inositol-1,4,5-triphosphate (InsP) generation, or nuclear factor of activated T cells (NFAT) nuclear localization.

Career Highlights

Philipp Mueller is affiliated with the University of Basel, where he conducts his research and develops his innovative ideas. His work has led to advancements in understanding immunosuppressant compounds and their mechanisms.

Collaborations

Some of his notable coworkers include Jean Pieters and Rajesh Jayac Han Dran. Their collaborative efforts contribute to the ongoing research and development in the field of immunology.

Conclusion

Philipp Mueller's contributions to immunology through his patent and research at the University of Basel highlight his role as an influential inventor in the scientific community. His work continues to pave the way for advancements in immunosuppressant therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…